Werewolf Therapeutics (NASDAQ:HOWL) Stock Price Down 0.8% – What’s Next?

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) fell 0.8% during trading on Friday . The company traded as low as $0.63 and last traded at $0.6536. 198,728 shares changed hands during trading, a decline of 52% from the average session volume of 417,370 shares. The stock had previously closed at $0.6590.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, January 21st. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. HC Wainwright reduced their target price on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Finally, Bank of America cut their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Stock Performance

The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock has a market cap of $31.73 million, a PE ratio of -0.40 and a beta of 0.77. The business’s 50-day moving average price is $0.71 and its 200-day moving average price is $1.15.

Insider Activity at Werewolf Therapeutics

In related news, Director Luke Evnin sold 108,606 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66. Following the sale, the director directly owned 2,550,674 shares of the company’s stock, valued at approximately $1,555,911.14. This represents a 4.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock in a transaction on Monday, November 24th. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96. Following the completion of the transaction, the insider directly owned 5,168,303 shares of the company’s stock, valued at $5,064,936.94. The trade was a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,901,619 shares of company stock worth $2,505,134 over the last three months. Company insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $28,000. Vontobel Holding Ltd. lifted its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter worth about $48,000. AQR Capital Management LLC purchased a new stake in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $92,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.